Regenerative Medicine & Biocybernetic Platform
Regentron is a regenerative medicine and biocybernetic platform company building the technology that activates, directs, and scales the human body's own regenerative capacity. 25 years of scientific work. 13 granted patents across a 20-asset IP portfolio. Our most de-risked evidence is a real-world clinical case series in fingertip regeneration — approximately 27 patients, follow-up up to 12 years, zero reported complications — where the intervention is the patented device itself. Two regulatory tracks: 510(k)/CE for the bioreactor equipment and BLA + IND / ATMP for the cell products. Pre-seed SAFE open; Series A planned 2027–2028.
Discover our platformThe Platform
We build an integrated platform of bioreactor systems, cellular engineering technologies, and precision delivery systems — each designed to activate and maximize what the body already knows how to do. Every technology serves one clinical goal: the restoration of normal anatomy. Built on 25 years of scientific work and an IP portfolio of 13 granted patents plus 6 assets with open Paris Convention priority windows available for PCT extension.
Five core technologies
Cells derived from the patient (autologous) or a healthy donor (allogeneic) are engineered into biocomposite cell aggregates — the biological building blocks for bone, cartilage, soft tissue, and systemic cell therapy applications. These aggregates — including spheroids and Organ Building Blocks (OBBs) — constitute biologics and ATMPs when administered to patients, each subject to their respective full regulatory pathway.
Patented aerosol method (RU 2814472) solves the fundamental bottleneck in tissue engineering: oxygen gradients that starve cells at depth, limiting viable tissue to ~200 microns. Enables clinical-scale production of thick-tissue constructs. No equivalent system exists. Companion patent RU 239614 covers the nebulizer delivery device — a system patent protecting both method and apparatus.
An implantable or attachable chamber that creates a controlled biological microenvironment at the injury site — delivering oxygen, cytokines, and nutrients to support transplanted biological products and amplify regeneration. The human body itself becomes the biological production environment, eliminating GMP-grade cell manufacturing costs. Validated in animal models; active patent applications under FIPS examination. Applications include burns, fingertip restoration, soft tissue defects, and orthopedic repair.
Precision systems for minimally invasive delivery of biological products. Robotic-assisted implantation and intraoperative biofabrication reduce procedural variability and enable standardized clinical protocols at scale.
Patient-specific digital modeling of defect anatomy, construct architecture, and treatment sequencing. Long-term development horizon — not a near-term commercial deliverable. Encompasses closed-loop real-time biological monitoring, wearable sensors integrated with regenerative devices, programmable robotic bioprinters, and patient lifecycle management systems. Positions Regentron at the convergence of bioengineering and precision medicine.
Clinical indications — five near-term programs + optionality
The same production infrastructure addresses unmet clinical needs across a family of programs. Five are near-term, each supported by investigator-initiated real-world clinical experience, an established competitor landscape, and a direct connection to the platform IP portfolio. Neurology (stroke / TBI / cerebral palsy) is the exception — held as longer-horizon optionality: its IP is still in preparation (not yet filed) and its clinical evidence is not yet substantiated, so it sits outside the near-term investment case.
Program 6 — Cellular Anti-Aging & Longevity: bone marrow harvest, stem cell isolation and banking (Cryocenter model), autologous stromal cell cultivation, and allogeneic cord blood cells for rejuvenation. Commercial precedent established. New patent applications planned.
"First-in-class regenerative medicine platform — biofabrication IP, in vivo delivery, and a connected clinic network — with a clear two-track regulatory architecture, recurring revenue economics, and multi-indication scalability."
Not to recreate biology artificially — but to activate, control, and scale the body's own regenerative mechanisms. The goal is the restoration of normal anatomy.
Patent Portfolio at a Glance
The platform is built as four technology layers — Production, in-vivo Microenvironment, Delivery, and long-horizon Monitoring & Integration. Each layer is paired with the technology Regentron holds, the patents that protect it, and the commercial products it enables. Six clinical programs draw on Layers 1–3 — five near-term, with neurology held as longer-horizon optionality.
The full portfolio map — with each patent and application listed by name under its layer, alongside the technology it protects and the commercial product it enables — lives on its own page.
Read the full portfolioRegulatory Strategy
Regentron operates two completely independent regulatory pathways. The bioreactor hardware — production equipment, delivery systems, the Regeneratron device — follows the medical device track: FDA 510(k)/De Novo and CE marking (MDR). The cell products manufactured inside that equipment — autologous spheroids, Organ Building Blocks (OBBs), and ATMPs — follow the biologics track: FDA Section 351 BLA + IND; EMA ATMP classification + CTA + MAA; UAE DoH-AD/MOHAP ATMP pathway. Device clearance does not extend to the therapy. Both tracks are real, both are necessary, and neither substitutes for the other.
24-Month Pre-seed to Series A Milestone Plan
Technology Readiness Assessment — TRL / MRL / IRL / RRL
Technology validated in laboratory and preclinical environment. Investigator-initiated clinical observations conducted in Russia. Target: FIH study initiated at UAE tertiary clinical partner under ATMP/IND sponsorship.
Manufacturing proof-of-concept demonstrated. Aerosol bioreactor patent (RU 2814472) closes the oxygen gradient bottleneck blocking MRL advancement across the field. Target: pilot-scale GMP-compatible workflow in 5–8 clinical partner installations.
System integration verified in laboratory. Two-track regulatory architecture — device (510k/CE) and biologics (BLA/ATMP) — are designed and mapped. Target: FDA 510(k) filed; first UAE clinical centre deployment operational.
Regulatory strategy defined across both tracks. Target: 510(k) application filed; IND/CTA pre-submission meeting conducted through clinical partner; ATMP classification obtained; first international registration initiated. *RRL framework per Trump & Horgan, Springer 2026.
Market Opportunity
Regenerative medicine is transitioning from laboratory promise to clinical and commercial reality. Capital is moving away from speculative organ fabrication toward infrastructure-layer platforms with near-term revenue. The window for first-movers is now.
See our strategyOsteoarthritis, bone non-union, cartilage loss. Largest near-term commercial segment. Regentron's cell aggregate technology validated preclinically here first.
Severe burns, chronic wounds, craniofacial defects, fingertip loss, and trauma reconstruction. The Regeneratron addresses all with one platform device.
$36.85B addressable market. No regenerative standard of care exists. The disc's avascular low-oxygen microenvironment is precisely what the aerosol bioreactor replicates — a structural advantage unique to the platform.
Stroke, TBI, spinal cord injury. A potential cell-therapy pathway based on cell-aggregate paracrine activity. Held as longer-horizon optionality — the IP is still in preparation (not yet filed) and the clinical evidence is not yet substantiated; outside the near-term investment case.
Retinal degeneration and corneal reconstruction using OBB-platform biologics produced on Regentron's bioreactor system. Pipeline expansion indication.
Stem cell banking, autologous stromal cell cultivation, allogeneic cord blood rejuvenation. Commercial precedent established. Clinic licensing model with recurring per-treatment revenue.
What exists today
The core technologies underlying the platform are not theoretical. A portfolio of 13 granted patents (11 invention patents, 1 utility model, 1 restored invention patent), 6 active applications under FIPS examination, and 1 in-preparation application — 20 IP assets in total — plus preclinical data and investigator-initiated clinical observations form a substantive foundation, independent of the funded program.
The platform's most advanced and most differentiated evidence: a documented real-world clinical case series in fingertip regeneration — approximately 27 patients (19 children aged 1–12 and 8 adults, adult follow-up up to 12 years), regeneration achieved with zero reported complications. This is the single de-risked, human, patent-aligned proof point in the portfolio — the intervention is the patented device itself (RU 2860621, granted 21.04.2026). A dedicated manuscript, "Partial Regeneration of Adult Fingertips," is in preparation for the Journal of Tissue Engineering and Regenerative Medicine, building on prior peer-reviewed clinical reports (2008, 2009). These are real-world clinical observations, not a registered trial.
Portfolio covers: bone spheroid production (RU 2744664, 2744732, 2744756, 2747087); cartilage spheroids (RU 2731314); minimally invasive delivery (RU 2748544, 2741206, 2750021, 2757157); aerosol bioreactor (RU 2814472 — crown jewel); fingertip regeneration bioreactor (RU 2860621 — granted 21.04.2026, core Regeneratron device asset, term to 19.09.2045, Paris Convention window open until 19.09.2026); in vivo bioreactor (RU 2715313 — restored effective 10.04.2026); nebulizer device utility model (RU 239614, Paris Convention window open until 29.09.2026).
Four retain open Paris Convention 12-month priority windows for priority-preserving PCT extension: distraction osteosynthesis spheroids (2025125573); alopecia areata cell therapy (2025131595); tissue-engineered construct and implant kit (2026105201); and a surgical-suture fixation device utility model (2026106767). Two further industrial-design applications — covering the in-vivo and tissue-engineering bioreactors — are in prosecution. Individual filing dates and priority deadlines are maintained internally and shared with qualified counterparties under NDA.
Method of Cellular Therapy for Stroke, Traumatic Brain Injury, and Cerebral Palsy — application in preparation, with a first-filing strategy structured to optimise the international priority position.
RU 2814472 and companion RU 239614 cover both the method and the apparatus — a system patent protecting the only known engineering solution to thick-tissue nutrient delivery at clinical scale. Viable tissue thickness: conventional systems ~200 microns vs. aerosol method — unlimited by oxygen gradient.
In vivo bioreactor prototype developed for tissue regeneration. In animal experiments, tissue within the Regeneratron showed sustained regenerative activity where control groups experienced rapid functional decline without the device. Active patent applications under FIPS examination.
Cell harvest → spheroid formation → bioreactor production → minimally invasive delivery → clinical observation → outcome data. This sequence has been operationally demonstrated in investigator settings in Russia. These are not formal IND-supervised trials and are not positioned as such — they establish biological proof-of-concept. The formal trial program will be conducted through clinical partners holding their own INDs and ATMP authorisations.
Conventional bioreactors are limited to roughly 200 microns of viable tissue — cells deeper inside a construct starve for oxygen. This has blocked every attempt to produce thick, clinically useful tissue at scale. First-generation tissue-engineering programs encountered this barrier at the transition from laboratory demonstration to clinical-scale production.
The aerosol method eliminates oxygen gradients entirely. Every cell receives equivalent nutrition regardless of position. The result: thick-tissue biologics that no conventional system can produce.
Our products require our equipment. The production loop is closed, IP-protected, and compounds in value with every new clinical partner installation worldwide. The portfolio is consolidating into a UAE-primary holding company, with a Delaware C-Corp alternative; chain-of-title documentation is available to qualified counterparties under NDA. 13 granted patents form the core, with several assets retaining open Paris Convention priority windows for priority-preserving PCT filings into the US, EU, China, and UAE.
The know-how embedded in the platform — including bioprinting methods and accumulated clinical experience — is broader and deeper than the IP formally protected in granted patents. The granted count is a floor, not a ceiling, of the defensive position, and the open-priority-window assets offer a narrow but still-available runway for international priority preservation.
Strategy & Next Steps
A structured trajectory through GLP preclinical validation, regulatory classification on both tracks, first-in-human trials, and a phased international clinical-partner rollout. UAE and GCC are the priority first deployment market. The pre-seed SAFE is open today; Series A is planned for 2027–2028.
Capital structure
Relationship-driven, long-horizon capital from family offices and strategic angels. Tranche 1: IP consolidation, PCT/US filings, independent IP due-diligence review. Tranche 2: regulatory classification on both tracks, GLP data audit, CMC, team transfer. Funds the 24-month program that builds the Series A data package.
Planned round. By Series A, the platform carries published GLP safety data, first-in-human study initiation, initial commercial revenue from the installed base, a peer-reviewed publication record, and an internationally defensible IP position — the evidence package institutional and sovereign investors require to underwrite at scale.
The UAE offers a compelling first deployment market: an active sovereign health mandate, well-capitalised institutional investors aligned with deep-tech platforms, and regulatory pathways that may enable earlier commercial deployment than FDA or CE timelines. Regentron is evaluating the UAE as a priority first market alongside other international jurisdictions. No formal regulatory or partnership agreements are in place at this stage; the strategic rationale and partnership profile under discussion remain confidential.
UAE positioning supports broader GCC regional rollout, aligned with regional healthcare-diversification objectives.
Regentron's commercial model is built around capital equipment placed with clinical partners (bioreactor systems, Regeneratron devices, delivery systems) and an ongoing supply of consumables, biological protocols, training, and quality systems. Clinical partners hold IND/CTA/ATMP sponsorship and administer therapy under their own regulatory authorisation. Recurring revenue accrues across the installed base and scales with the partner network rather than with any single product approval — decoupling Regentron's revenue trajectory from the biologics regulatory timeline.
Team
The platform was built by scientists who have spent their careers at the intersection of cell biology, tissue engineering, and biomedical device development.
25+ years in regenerative medicine and cellular technologies. The scientific architect of Regentron's core platform — in vivo bioreactor systems, biocomposite cell aggregate engineering, and minimally invasive cell delivery. Candidate of Medical Sciences. Publications in Tissue Engineering, ACS Omega, and International Journal of Molecular Sciences. Holds 48 personal patents — forming the core of the company's IP portfolio.
35+ years of experience. One of the founding figures of global 3D bioprinting — co-authored the first scientific publication on organ printing in 2003. Led development of the first bioprinted thyroid successfully transplanted into a mouse. Pioneer in magnetic levitational bioassembly and robotic bioprinter development. H-index 58; 22,000+ citations; 200+ peer-reviewed publications.
Research & Publications
A 12-paper publication program targeting Q1 peer-reviewed journals — structured in three waves across the 24-month pre-seed period. Each paper builds institutional credibility, reinforces IP positions, and constitutes the scientific validation package required for Series A.
Regentron's scientific team is actively publishing. Our first peer-reviewed correspondence is live in Surgical Innovation (SAGE, 2026) — a direct exchange with Vladimir Mironov, one of the founding figures of organ bioprinting. Additional papers from our 12-paper program will appear here as they are accepted in indexed journals. Each publication builds the institutional credibility record required for Series A.